Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lifted by Westhampton Capital LLC

Westhampton Capital LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,063 shares of the biopharmaceutical company’s stock after buying an additional 170 shares during the quarter. Westhampton Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $757,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $37,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Royal Bank of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $687.27 on Thursday. The company’s fifty day moving average is $724.48 and its two-hundred day moving average is $930.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $75.52 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 1.59 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.